###begin article-title 0
###xml 15 24 15 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP - 12 </italic>
###xml 96 99 96 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 103 115 103 115 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1, 9 and 12 </italic>
Association of MMP - 12 polymorphisms with severe and very severe COPD: A case control study of MMPs - 1, 9 and 12 in a European population
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 210 235 210 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">matrix metalloproteinase </italic>
###xml 236 239 236 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 399 402 399 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
Genetic factors play a role in chronic obstructive pulmonary disease (COPD) but are poorly understood. A number of candidate genes have been proposed on the basis of the pathogenesis of COPD. These include the matrix metalloproteinase (MMP) genes which play a role in tissue remodelling and fit in with the protease - antiprotease imbalance theory for the cause of COPD. Previous genetic studies of MMPs in COPD have had inadequate coverage of the genes, and have reported conflicting associations of both single nucleotide polymorphisms (SNPs) and SNP haplotypes, plausibly due to under-powered studies.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 109 112 109 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 141 149 <span type="species:ncbi:9606">patients</span>
To address these issues we genotyped 26 SNPs, providing comprehensive coverage of reported SNP variation, in MMPs- 1, 9 and 12 from 977 COPD patients and 876 non-diseased smokers of European descent and evaluated their association with disease singly and in haplotype combinations. We used logistic regression to adjust for age, gender, centre and smoking history.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
Haplotypes of two SNPs in MMP-12 (rs652438 and rs2276109), showed an association with severe/very severe disease, corresponding to GOLD Stages III and IV.
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 342 344 342 344 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 410 417 410 417 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
Those with the common A-A haplotype for these two SNPs were at greater risk of developing severe/very severe disease (p = 0.0039) while possession of the minor G variants at either SNP locus had a protective effect (adjusted odds ratio of 0.76; 95% CI 0.61 - 0.94). The A-A haplotype was also associated with significantly lower predicted FEV1 (42.62% versus 44.79%; p = 0.0129). This implicates haplotypes of MMP-12 as modifiers of disease severity.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 349 350 349 350 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B1">1</xref>
###xml 546 547 546 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B2">2</xref>
###xml 693 694 693 694 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B3">3</xref>
Chronic Obstructive Pulmonary Disease (COPD) is a major cause of morbidity and mortality worldwide. The World Health Organisation's Global Burden of Disease and Risk Factors project estimates that in 2001, COPD was the fifth leading cause of death in high-income countries and the sixth leading cause of death in countries of low and middle income [1]. Cigarette smoking is the main aetiological risk factor in disease development. However, only about 10 - 20% of smokers develop clinically significant COPD though this may be an under-estimate [2]. Furthermore, there is variability between smokers who have similar levels of smoke exposure, with many developing milder forms of the disease [3]. These observations suggest that underlying genetic factors contribute to either disease susceptibility or protection.
###end p 10
###begin p 11
###xml 149 150 149 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 406 407 406 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B4">4</xref>
###xml 515 539 515 539 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">matrix metalloproteinase</italic>
###xml 542 545 542 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
A widely accepted hypothesis of COPD causation is an imbalance of proteolytic enzymes and their inhibitors based on the observation that severe alpha1-antitrypsin deficiency predisposes cigarette smokers to the development of pulmonary emphysema in early adult life. This is thought to be due to uninhibited neutrophil elastase (NE) activity degrading elastin, a major component of lung connective tissue [4]. There are a number of other proteolytic enzymes also capable of degrading elastin, most particularly the matrix metalloproteinases (MMPs), a family of potent proteinases that degrade all the major protein components of the extra-cellular matrix (ECM).
###end p 11
###begin p 12
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 108 112 108 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP </italic>
###xml 202 208 202 208 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-1 </italic>
###xml 227 228 227 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B5">5</xref>
###xml 238 245 238 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 331 332 331 332 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B6">6</xref>
###xml 347 354 347 354 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 453 456 453 456 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B7">7</xref>
###xml 496 498 496 498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B12">12</xref>
###xml 571 588 571 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMPs-1, 9 and 12 </italic>
###xml 621 627 621 627 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-1 </italic>
###xml 631 638 631 638 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 690 696 690 696 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9 </italic>
###xml 810 813 810 813 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 816 825 816 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 and 12 </italic>
###xml 864 866 864 866 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 904 910 904 910 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9 </italic>
###xml 973 975 973 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B14">14</xref>
###xml 1046 1050 1046 1050 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP </italic>
###xml 1296 1312 1296 1312 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP 1, 9 and 12 </italic>
###xml 1344 1345 1344 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
###xml 1526 1528 1526 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B15">15</xref>
###xml 170 185 <span type="species:ncbi:10090">Transgenic mice</span>
###xml 254 258 <span type="species:ncbi:10090">mice</span>
###xml 415 423 <span type="species:ncbi:9606">patients</span>
MMPs play a key role in tissue remodelling and repair and there is significant evidence that members of the MMP family may also play an important role in COPD pathology. Transgenic mice over-expressing MMP-1 develop emphysema [5], whilst MMP-12 knockout mice are protected from emphysema despite prolonged cigarette smoke exposure[6], implicating MMP-12 as a compelling emphysema determinant in this model. In COPD patients a range of studies implicate MMPs in the pathogenesis of the disease [7-12]. A number of studies have reported associations of genetic variants in MMPs-1, 9 and 12 with COPD or related phenotypes. MMP-1 and MMP-12 are located in close proximity on chromosome 11 and MMP-9 is located on chromosome 20. Reported associations of these genes with COPD include associations of haplotypes of MMPs- 1 and 12 with rate of decline in lung function [13] in Caucasians and association of an MMP-9 promoter polymorphism with emphysema in a Japanese population [14]. However, there are conflicting data on the potential involvement of MMP variation in COPD. This likely reflects a number of issues relating to false positives in case- control studies or a lack of power due to relatively small sample size and the limited number of single nucleotide polymorphisms (SNPs) investigated, MMP 1, 9 and 12 studies are summarised in table 1. Other issues that contribute to lack of reproducibility include variation in the definition of cases and controls, improper matching of cases and controls and ethnic differences [15]. The results therefore need to be interpreted with caution.
###end p 12
###begin p 13
Previous association studies performed in COPD
###end p 13
###begin p 14
###xml 209 212 209 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1, 9 </italic>
###xml 224 227 224 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12 </italic>
###xml 381 385 381 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP </italic>
###xml 69 77 <span type="species:ncbi:9606">patients</span>
To address the major issues, a European cohort of 977 Caucasian COPD patients and 876 non-diseased smoking controls with complete genotyping information was used to evaluate the relationship of 26 SNPs within MMPs- 1, 9 and 12 with COPD and to investigate associations with GOLD -defined severity phenotypes. These tagging SNPs provide coverage of most of the variation within the MMP genes.
###end p 14
###begin title 15
Methods
###end title 15
###begin title 16
Subjects
###end title 16
###begin p 17
###xml 361 363 361 363 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B16">16</xref>
###xml 364 366 364 366 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
###xml 1070 1078 <span type="species:ncbi:9606">patients</span>
COPD and non-diseased smoking control subjects were recruited from six European centres. Only white Caucasians were recruited. Study approval was obtained from appropriate local committees to each recruitment centre. Informed consent was obtained from all subjects. The resource of COPD patients and non-diseased smoking controls has been described previously [16-19] and is one of the largest reported to date. The number of subjects recruited from each centre was as follows. Barcelona (Spain): 70 controls and 138 cases; Bristol (UK): 152 controls and 129 cases; Dublin (Ireland): 195 controls and 196 cases; Edinburgh (UK): 81 controls and 168 cases; Leiden (the Netherlands): 216 controls and 188 cases; and Pisa (Italy): 198 controls and 198 cases. It should be noted that the total resource consisted of 1017 COPD patients and 912 controls. If strict criteria for genotyping were not met or assay design proved difficult, results were not included in the present analysis to minimise potential errors. This resulted in completed unequivocal genotypes in 977 COPD patients and 876 controls.
###end p 17
###begin p 18
###xml 229 231 229 231 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 270 271 268 269 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 459 461 452 454 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
Briefly, recruitment criteria were agreed by a panel of respiratory physicians with an interest in COPD and included a firm clinical diagnosis of COPD; airflow limitation as indicated by (Forced Expiratory Volume in 1 Second) FEV1 </= 70% normal predicted values and FEV1/(Forced Vital Capacity) FVC < 0.7; no significant reversibility with salbutamol (>/= 200 mug) and a smoking history of >/= 20 pack years with matched smoking history for the controls. FEV1 is measured using a spirometer, it is the maximum volume of air that can be forcibly breathed out in one second after full inspiration. FVC is the maximum volume of air that can be forcibly breathed out after full inspiration.
###end p 18
###begin p 19
###xml 682 683 682 683 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 711 713 711 713 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 778 779 776 777 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 807 809 805 807 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 882 883 878 879 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 911 913 907 909 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 930 932 926 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B20">20</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 181 189 <span type="species:ncbi:9606">Patients</span>
###xml 521 529 <span type="species:ncbi:9606">patients</span>
Patients were excluded from the study if they had an established diagnosis of asthma, lung cancer, history of atopy, known AAT deficiency or a serum AAT level of less than 1.0 g/L. Patients with acute exacerbations four weeks preceding study assessment were also excluded. This was an agreed part of the protocol to enable future studies, where appropriate, to investigate correlations of genotypes with quantitative traits such as lung function or concentrations of analytes in biological fluids. We did not recruit any patients with Global Obstructive Lung Disease (GOLD) Stage I. Disease severity was classified according to GOLD as follows: GOLD Stage II (moderate disease): FEV1/FVC ratio of < 0.70 and FEV1 predicted >/= 50% and < 80%; GOLD Stage III (severe disease): FEV1/FVC ratio of < 0.70 and FEV1 predicted >/= 30% and < 50%; and GOLD Stage IV (very severe disease): FEV1/FVC ratio of < 0.70 and FEV1 predicted < 30% [20].
###end p 19
###begin p 20
###xml 61 63 61 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 86 87 84 85 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1</sub>
###xml 162 170 <span type="species:ncbi:9606">patients</span>
Control subjects with no evidence of airflow obstruction (FEV1 and FVC >/= 80% and FEV1/FVC > 0.70) were recruited at each centre with attempted matching to COPD patients for ethnicity, age, gender and smoking history. Exclusion criteria were as described for cases and additionally included family history of COPD. However, complete matching was not achieved due to a high proportion of smokers aged 65 or over having evidence of some pulmonary obstruction, thereby excluding them from recruitment as controls.
###end p 20
###begin p 21
###xml 31 35 31 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP </italic>
###xml 370 372 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B21">21</xref>
We compared the frequencies of MMP SNPs for each centre in cases and controls to look for population stratification. For the genes under study, population stratification would have been reflected in different frequencies in the centre to centre comparisons. No such differences were observed. These findings are in keeping with previous observations on this sample set [19] and with data obtained from British samples reported by the Wellcome Trust Case Control Consortium in genome- wide association studies where stratification has been shown to be not as significant an issue in the British population as previously thought [21]; similar findings are likely for western European populations.
###end p 21
###begin title 22
Study Population Characteristics
###end title 22
###begin p 23
###xml 61 62 61 62 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T2">2</xref>
###xml 359 360 359 360 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T3">3</xref>
###xml 295 303 <span type="species:ncbi:9606">patients</span>
The study population characteristics are summarised in Table 2. Despite attempts to match cases and controls there were significant differences observed and adjustments were made by logistic regression to take this into account in the statistical analysis. The characteristics of recruited COPD patients across the GOLD severity categories are shown in Table 3.
###end p 23
###begin p 24
Characteristics of Controls and COPD subjects
###end p 24
###begin p 25
###xml 60 67 <span type="species:ncbi:9606">persons</span>
Values indicated are means +/- SD. Pack Years missing for 6 persons.
###end p 25
###begin p 26
###xml 24 32 <span type="species:ncbi:9606">patients</span>
Characteristics of COPD patients according to GOLD classification of disease severity
###end p 26
###begin p 27
###xml 66 73 <span type="species:ncbi:9606">persons</span>
Values indicated are means +/- SD. Pack years missing for 3, 2, 1 persons per classification respectively.
###end p 27
###begin title 28
Power Calculations
###end title 28
###begin p 29
Using Quanto software for the power calculations, with an autosomal dominant model, this study has 80% power to detect an odds ratio of 1.5 with an allele frequency of 0.1.
###end p 29
###begin title 30
SNP Selection and Haplotypes
###end title 30
###begin p 31
###xml 26 29 26 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 548 550 548 550 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B22">22</xref>
###xml 597 599 597 599 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 1183 1184 1181 1182 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
SNP identification within MMPs- 1, 9 and 12 genes was carried out using information obtained from a combination of databases including HapMap and Seattle SNPs. SNPs with a minor allele frequency of less than 5% were excluded from the study, as these were likely to be insufficiently powered to detect association. SNPs lacking any validation status as described on the dbSNP database were also excluded. Further narrowing of SNP selection was based on putative function described in the databases and predicted function by the FastSNP web-service [22]. Where SNPs were in linkage disequilibrium (r2 >/= 0.8) in previously reported Caucasian populations (HapMap, National Heart Lung and Blood Institute's (NHLBI) Programs for Genomic Applications European (PGA EUR) population, or Environmental Gene Project Centre d'Etude du Polymorphisme Humain (EGP CEPH) European population) a single tagging SNP was chosen for genotyping, thus minimising the number of SNPs that needed to be investigated and reducing the number of statistical tests required. This resulted in 26 SNPs across the three genes being selected for analysis. Information on the 26 genotyped SNPs is indicated in Table 4. The SNPs were selected as described below.
###end p 31
###begin p 32
SNPs selected for genotyping
###end p 32
###begin p 33
SNPs are shown in 3' to 5' order. Contig Position numbering is relative to HuRef NCBI build 36.3. SNPs 6 and 13 (rs numbers 17884110 and 1799750 respectively) represent an insertion/deletion polymorphism. Amino acid changes are shown where present.
###end p 33
###begin title 34
MMP-1
###end title 34
###begin p 35
###xml 324 329 324 329 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-1</italic>
A panel of 21 validated SNPs was identified within the gene and its promoter region. However, rs488178 was found to be unsuitable for design and was excluded. Consideration of the linkage disequilibrium between the SNPs resulted in a final panel of 13 SNPs being genotyped, giving 87% coverage of validated SNP variation in MMP-1.
###end p 35
###begin title 36
MMP-9
###end title 36
###begin p 37
###xml 442 447 442 447 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9</italic>
A panel of 23 validated SNPs was identified within the gene and its promoter region from the databases, which covered all known validated SNPs within the region. However, rs25650 was found to be non-polymorphic in the study cohort and was excluded from further analysis. Consideration of the linkage disequilibrium between the SNPs resulted in a final panel of 8 tagged SNPs being genotyped, giving 96% coverage of validated SNP variation in MMP-9.
###end p 37
###begin title 38
MMP-12
###end title 38
###begin p 39
###xml 433 439 433 439 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12</italic>
A panel of 17 validated SNPs was identified within the gene and its promoter region, a selection which covered all known validated SNPs within the region. However, rs28360355, rs28381675 and rs28360356 were found to be unsuitable for assay design and were excluded. Consideration of the linkage disequilibrium between the SNPs resulted in a final panel of five SNPs being genotyped, giving 82% coverage of validated SNP variation in MMP-12.
###end p 39
###begin title 40
Genotyping of Study Samples
###end title 40
###begin p 41
Full genotyping information was available in 977 COPD cases and 876 controls. Genotyping was carried out commercially by K- Bioscience using KASPar, an in-house validated competitive allele-specific polymerase chain reaction SNP genotyping system which utilises fluorescence resonance energy transfer quencher cassette oligonucleotides. Taqman, a rapid fluorophore based real- time PCR method, was used to genotype SNPs found to be unsuitable for KASPar assay design. As a quality control measure, approximately 5% of samples were genotyped in duplicate to check for concordance. There was 100% concordance between the duplicates, satisfying criteria for the assays to be accepted for further analysis.
###end p 41
###begin title 42
Statistical Analysis
###end title 42
###begin p 43
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 407 409 405 407 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B24">24</xref>
###xml 515 516 513 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="F1">1</xref>
Each of the SNPs in the three genes was analyzed for Hardy-Weinberg equilibrium (HWE) using PROC ALLELE in SAS/Genetics Release 9.1.3 [23], an empirical p-value of </= 0.01 was used as a cut-off, to reduce the likelihood of reporting false positives. To examine linkage disequilibrium, the correlation coefficient between SNP pairs within each gene in cases and controls was calculated using Haploview 4.1 [24] a software package that computes linkage disequilibrium and haplotype blocks from genotype data (figure 1).
###end p 43
###begin p 44
###xml 0 48 0 48 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">LD plot in controls of SNPs in MMPs- 1, 9 and 12</bold>
###xml 64 66 64 66 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
###xml 275 277 275 277 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
LD plot in controls of SNPs in MMPs- 1, 9 and 12. Estimated as r2 using Haploview 4.1 output. SNP codes are provided in order of location along each gene; dark grey squares depict strong LD (1.0) with strong confidence, pale grey and white regions represent low LD, and the r2 value is provided within each box. SNP positions are demonstrated 5' to 3' relative to contig postion (HuRef NCBI build 36.3).
###end p 44
###begin p 45
###xml 58 62 58 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP </italic>
Analyses of allele and genotype frequencies for the three MMP genes were performed using PROC ALLELE in SAS/Genetics. The adjusted p-values for genotype and allele frequencies were obtained using PROC LOGISTIC in SAS, adjusting for age, sex, smoking and centre.
###end p 45
###begin p 46
###xml 17 20 17 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 97 99 97 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B25">25</xref>
###xml 121 123 121 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B26">26</xref>
###xml 212 218 212 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-9 </italic>
###xml 345 351 345 351 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-1 </italic>
###xml 355 358 355 358 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 359 362 359 362 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12 </italic>
As haplotypes of MMPs have been reported to be associated with COPD or decline in lung function [13,25], using FAMHAP18 [26] we examined haplotypes in all possible SNP combinations based on the eight SNPs in the MMP-9 gene on chromosome 20 and also in all combinations consisting of four or fewer SNPs from the 16 analysable SNPs (see below) in MMP-1 and MMP-12 combined on Chromosome 11. We considered only up to four haplotypes because of the optimal power considerations in FAMHAP18. We compared haplotype distributions for all cases versus controls, for GOLD severity III and IV cases versus controls and for GOLD severity IV only versus controls. We used as a cut off criterion a p < 0.01 for a significance test on the contingency table of all possible simulated haplotypes within possible SNP combination in cases and controls.
###end p 46
###begin p 47
###xml 355 357 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B27">27</xref>
###xml 358 360 356 358 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B28">28</xref>
###xml 395 397 393 395 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B29">29</xref>
P-values were based on 10,000 simulations and since for this sample size the 95% confidence limits for 0.01 are +/- 0.002, we report all comparisons with a p-value less than 0.012. To allow for multiple testing we used the maximum estimated q-value that corresponds to p-values </= 0.012 with a high stringency estimate of the false discovery rate (FDR) [27,28] (using the q-value Package in R [29]).
###end p 47
###begin p 48
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
Odds ratios for haplotype and individual SNP allele distributions are relative to the common haplotype or allele. The adjusted odds ratios with 95% confidence intervals, adjusting for age, sex, smoking and centre are estimated for haplotypes by weighted logistic regression as described previously [19] (PROC LOGISTIC in SAS), and for alleles by standard logistic regression.
###end p 48
###begin p 49
###xml 23 25 23 25 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B23">23</xref>
###xml 111 113 111 113 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 221 223 221 223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B19">19</xref>
Using PROC GLM in SAS [23] the quantitative trait associations between SNPs or haplotypes and the phenotype FEV1 were tested by multivariate regression using a similar weighted method to that used in logistic regression [19], adjusting for age, sex, smoking and centre. The adjusted means were determined using the LSMEANS option.
###end p 49
###begin title 50
Results
###end title 50
###begin title 51
Quality Control
###end title 51
###begin p 52
###xml 50 51 50 51 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T4">4</xref>
###xml 412 418 412 418 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-1 </italic>
###xml 301 309 <span type="species:ncbi:9606">patients</span>
The full list of SNPs analysed are shown in Table 4. The overall genotype call rate was 95% (range, 92-96%), and the accuracy was 100% according to duplicate genotyping of > 5% of samples. The use of high stringency cut-offs resulted in the loss of some genotyping data and reduction in the number of patients studied from the original sample set. Significant deviation from HWE was observed in controls for two MMP-1 SNPs, rs470358 and rs2071230. The assays for these two SNPs were sub-optimal, with overlap in the signals observed for homozygotes and hetrozygotes.
###end p 52
###begin title 53
Association Analysis
###end title 53
###begin p 54
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 992 993 992 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T5">5</xref>
###xml 1002 1003 1002 1003 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T6">6</xref>
###xml 404 412 <span type="species:ncbi:9606">patients</span>
Table 5 compares the genotype frequencies between all cases and controls for the 26 SNPs analysed. There were no significant differences at p < 0.01 in either the crude analysis or the analysis adjusted for age, sex, smoking levels and centre. To evaluate potential genetic contribution to more severe manifestations of the disease, those with moderate levels of disease were excluded from the cases and patients with either severe or very severe disease (GOLD groups III and IV) were compared to controls. This comparison was also performed for cases with very severe disease only (GOLD group IV). This approach enabled evaluation of the potential underlying genetic contribution to disease severity phenotype within the study population with least reduction in power. While unadjusted analysis indicated significant associations between genotype frequencies of SNP 18 and more severe disease, these became non-significant with p > 0.01 when adjusted for age, sex, smoking and centre (Table 5). Table 6 analyses allele relationships for all SNPs.
###end p 54
###begin p 55
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 6 18 6 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1, 12 and 9 </italic>
MMPs -1, 12 and 9 - Genotype frequencies in Controls and Cases
###end p 55
###begin p 56
*For GOLD classification severity III and IV, and severity IV, only SNPs with an unadjusted significant (p-value </= 0.01) genotypes difference between cases and controls are reported.
###end p 56
###begin p 57
** P-values adjusted by logistic regression for age, sex, smoking and centre.
###end p 57
###begin p 58
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 6 18 6 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1, 12 and 9 </italic>
MMPs -1, 12 and 9 - Allelic frequencies in Controls and Cases
###end p 58
###begin p 59
*p-values adjusted by logistic regression for age, sex, smoking and centre.
###end p 59
###begin p 60
** Odds ratios are relative to the major allele.
###end p 60
###begin p 61
###xml 379 380 379 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T7">7</xref>
###xml 782 784 782 784 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 </sup>
As described in the Methods, we then examined all possible haplotypes consisting of between two and four SNPs in the same chromosome for differences between the case groups defined above and controls. Adjusting for multiple testing the only significant differences in haplotype distributions were found when severe/very severe (GOLD groups III and IV) cases were involved. Table 7 shows the seven significant haplotypes together with their unadjusted p-values. Since the haplotype comprising SNPs 14 and 18 (p = 0.0086) is a subset of all the other significant combinations identified, we deduce that the significant results are a consequence of the association of SNPs 14 and 18 with disease severity in COPD, despite the apparently high false discovery rate of 0.54. The low LD (r2 = 0.083) in controls between these two SNPs indicates the separate involvement of both SNPs in this association.
###end p 61
###begin p 62
###xml 0 15 0 15 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP - 1 and 12 </italic>
MMP - 1 and 12 Risk Haplotypes related to disease GOLD severity III and IV combined versus controls
###end p 62
###begin p 63
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
+ P-values are by Monte-Carlo simulation on 10,000 runs.
###end p 63
###begin p 64
###xml 6 7 6 7 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T8">8</xref>
###xml 61 68 61 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 275 282 <span type="species:ncbi:9606">Persons</span>
Table 8 shows the actual haplotypes of SNPs 14 and 18 in the MMP-12 gene and their frequencies in severe/very severe disease (GOLD Stages III and IV) compared to controls. For completeness the table also shows the relationship of the alleles of each SNP alone with severity. Persons with the rare G allele of either SNPs 14 or 18 were protected against severe/very severe COPD. Compared with the common A-A haplotype of SNPs 14 and 18, subjects with the G allele at either locus had a significantly reduced risk of having severe/very severe COPD. Of note, and of importance from a population perspective, is that, based on the distribution in controls, 18% of the European population have at least one of these protective haplotypes, with an average risk 0.76 (95% CI: 0.61 to 0.94) times less than those with the common haplotype.
###end p 64
###begin p 65
###xml 0 3 0 3 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 5 8 5 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12 </italic>
MMP- 12 haplotypes significantly different between GOLD Classification III and IV cases and controls
###end p 65
###begin p 66
###xml 0 2 0 2 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+ </sup>
+ P-values are by Monte-Carlo simulation on 10,000 runs.
###end p 66
###begin p 67
###xml 0 3 0 3 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">++ </sup>
++ Adjusted for choice of the most significant 2 x 2 table with collapsed data.
###end p 67
###begin p 68
* Odds ratios are relative to the common allele or haplotype.
###end p 68
###begin p 69
** Adjusted for age, sex, smoking and centre.
###end p 69
###begin p 70
###xml 87 94 87 94 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 162 164 162 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 391 393 391 393 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 550 552 550 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </sub>
###xml 445 453 <span type="species:ncbi:9606">patients</span>
Confining the analysis to cases only we examined the relationship between variation in MMP-12 SNPs 14 and 18 and their haplotypes to severity of disease using FEV1 as a severity measure. Weighted multivariate regression models, adjusting for age, sex, smoking and centre were used to test for the associations. Those individuals with the haplotype A-A had a significantly lower predicted FEV1 (42.62% versus 44.79%, p = 0.0129) when compared to patients with any haplotypes containing a G allele. We did not find a significant association between FEV1 and the alleles in SNP 14 and SNP 18 singly.
###end p 70
###begin title 71
Discussion
###end title 71
###begin p 72
###xml 69 72 69 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 246 249 246 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 272 275 272 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 307 310 307 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 378 379 378 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T1">1</xref>
A number of studies have reported on the role of genetic variants of MMPs in genetic susceptibility to COPD or related phenotypes. However, the majority of studies have concentrated on the three well known promoter polymorphisms of these genes - MMP1-1607-/G (rs1799750), MMP9 -1562 C/T (rs3918242) and the MMP12-82A/G (rs2276109) in comparatively smaller sample numbers (Table 1).
###end p 72
###begin p 73
###xml 78 81 78 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 595 603 <span type="species:ncbi:9606">patients</span>
Our study reports on the largest and most extensive screen of SNPs within the MMPs- 1, 9 and 12 genes undertaken to date and include the three promoter SNPs or SNPs that are in LD with the promoter SNPs which have been previously reported, in a larger sample size. All SNPs evaluated in the final analysis were in HWE in controls, had high call rates and concordant duplicates by genotyping, suggesting that this study was not likely to be influenced by genotyping errors. All subjects were of European descent and any potential effects of population stratification were minimised by recruiting patients and controls from each centre and confirmed by the fact that SNP genotype frequencies in the controls for each centre were found to be similar. Given the greater level of power in our study it is unlikely that effects of the magnitude observed in previous, less powered studies, have been missed. However, there may be subtle differences in phenotypes and association with quantitative traits such as lung function decline in the previous studies that we were not able to test. This is in part due to multiple testing issues, investigating numerous phenotypes could lead to false positives. Also, phenotype data for some clinical endpoints such as CT scans for emphysema has not been collected for our population. Although, this may cause difficulties with planning functional work, future work testing associated SNP's in other COPD cohorts characterised for specific phenotypes will address this.
###end p 73
###begin p 74
###xml 4 12 <span type="species:ncbi:9606">patients</span>
The patients with very severe disease had a mean age that was less than the severe and moderate groups and this may reflect a survival bias.
###end p 74
###begin p 75
###xml 14 20 14 20 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP's </italic>
###xml 22 24 22 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </italic>
###xml 28 30 28 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">9 </italic>
###xml 195 200 <span type="species:ncbi:9606">human</span>
We found that MMP's - 1 and 9 were not associated with COPD in our populations. This is an interesting result as these genes have previously been implicated in COPD by both rodent and a range of human studies. In the previous case control association studies, many of the associations in MMP's 1 and 9 have been demonstrated in non - Caucasian populations. Further to this, some of the studies use different phenotypic end points.
###end p 75
###begin p 76
###xml 8 11 8 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 670 672 670 672 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 673 675 673 675 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 872 874 872 874 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B30">30</xref>
###xml 977 980 977 980 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 981 983 981 983 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 </italic>
###xml 1012 1014 1012 1014 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B13">13</xref>
###xml 1089 1095 1089 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al </italic>
###xml 1096 1098 1096 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B31">31</xref>
###xml 1130 1137 1130 1137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 1487 1494 1487 1494 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
For the MMP-12 gene, we identified haplotypes associated with two SNPs, SNP 14 (rs652438) and SNP 18 (rs2276109), which showed associations with severe/very severe COPD. The associations with GOLD Stage III and IV disease suggest that these SNPs may play a modifier role in disease severity. We also showed that haplotypes of the two SNPs were significantly related to severity within the COPD cases, as determined by the quantitative levels of FEV1 within the cases. Those with the haplotypes A-G, G-A or G-G had higher FEV1 levels. It is of note that, evaluation of the association of SNP 18 (rs2276109) with COPD has been previously examined, but no effect was seen [13,30]. This probably reflects underpowered studies and the need to examine disease severity. SNP 14 (rs652438) has been previously shown to be associated with smoking induced COPD in a Chinese cohort [30], as well as being associated with a decline in lung function when considered as a haplotype with the MMP-1 promoter SNP 13 (rs1799750) [13]. The recent genome wide association study (GWAS) study in COPD by Pillai et al [31] didn't report association for MMP-12 in COPD even though there are SNPs in full linkage disequilibrium with rs2276109 and rs652438 on the illumina 550k platform used. However, this does not preclude the SNP's involvement in disease as they may have significance but not to genome wide level, access to the primary data would be of interest regarding this. Furthermore, in our population MMP-12 SNPs are associated with severe forms of COPD after haplotypic association, unlike the GWAS which is total COPD cases versus control population using single SNP association.
###end p 76
###begin p 77
###xml 691 692 691 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="T7">7</xref>
Although we noted a trend (p = 0.054) for association of SNP 14 (rs652438) with disease, our strict cut-off for significance indicates that it may require a much larger sample size to be confident of such an association. It is of note, however, that SNP 14 (rs652438) is a constituent of all the haplotypes found to be associated with severe/very severe disease, suggesting that it contributes to disease severity in COPD. It is also possible that this locus, or genetic variants in LD with rs652438, may affect susceptibility to COPD in the Chinese population. Whilst we did observe three haplotypes involving SNPs 13, 14 and 18 which were associated with severe/very severe disease (Table 7), there was no significant association for a 2-SNP haplotype with SNPs 13 and 14 only.
###end p 77
###begin p 78
###xml 382 385 382 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 386 389 386 389 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12 </italic>
###xml 483 486 483 486 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 487 490 487 490 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12 </italic>
###xml 591 598 591 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 515 523 <span type="species:ncbi:9606">patients</span>
SNP 18 (rs2276109) with the alleles A/G is a known functional variant where the A allele shows a higher affinity for the transcription factor activator protein-1 (AP-1), resulting in increased expression in gene reporter assays. In the current study, the A-A haplotype composed of SNP 18 (rs2276109) and SNP 14 (rs652438) is over-represented in the cases, suggesting that increased MMP-12 levels may contribute to COPD pathogenesis. This is consistent with observations of increased MMP-12 activity in the lungs of patients with COPD and with observations in a rodent model of disease where MMP-12 knock-outs are protected against smoking-induced emphysema.
###end p 78
###begin p 79
###xml 26 32 26 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">et al </italic>
###xml 33 35 33 35 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="B32">32</xref>
###xml 47 57 47 57 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMPs 1, 3 </italic>
###xml 61 64 61 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">12 </italic>
###xml 169 180 169 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP - 12's </italic>
A recent paper by McAloon et al [32], screened MMPs 1, 3 and 12 relatively comprehensively in AATD with associations being found with gas transfer. This could allude to MMP - 12's role in parenchymal disease pathophysiology rather than airways disease, especially when considered with association in this study against severe forms of COPD and in previous studies with emphysema.
###end p 79
###begin title 80
Conclusions
###end title 80
###begin p 81
###xml 89 96 89 96 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
###xml 172 175 172 175 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP</italic>
###xml 178 186 178 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1 and 9 </italic>
###xml 232 239 232 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MMP-12 </italic>
While this study provides suggestive evidence for a contribution of genetic variation in MMP-12 to disease severity in COPD, we do not find evidence for the involvement of MMPs- 1 and 9 in COPD. This merits further investigation of MMP-12 associations in similar or larger cohorts.
###end p 81
###begin title 82
Competing interests
###end title 82
###begin p 83
The authors declare that they have no competing interests.
###end p 83
###begin title 84
Authors' contributions
###end title 84
###begin p 85
The authors IH, SC, JL, LD, COC and NK made substantial contribution to the conception and design of the study, and analysis and interpretation of the data. Whilst SJ, KM, TG, JR, RR, AM, SD, VK, WM, JS, PH, MM and SM made a substantial contribution to the collection of the resource and an intellectual contribution to the study design.
###end p 85
###begin title 86
Pre-publication history
###end title 86
###begin p 87
The pre-publication history for this paper can be accessed here:
###end p 87
###begin p 88

###end p 88
###begin title 89
Acknowledgements
###end title 89
###begin p 90
###xml 286 289 286 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">th </sup>
We thank Ann Hann (Bristol), Breda Callaghan and Gemma Hogan (Dublin), Joyce Barr (Edinburgh), Clara Kolster-Bijdevaate (Leiden) for assisting with recruitment; G. Catapano E. Fornai and C. Carli for clinical and technical assistance in Pisa. This work was supported by European Union 5th Framework Programme Grant QLG1-CT-200-01012 and the Medical Research Council UK. J. Lotya was supported by a grant from the Health Research Board (Ireland).
###end p 90
###begin article-title 91
Global burden of COPD: risk factors, prevalence, and future trends
###end article-title 91
###begin article-title 92
ABC of chronic obstructive pulmonary disease. Definition, epidemiology, and risk factors
###end article-title 92
###begin article-title 93
COPD: the dangerous underestimate of 15%
###end article-title 93
###begin article-title 94
The Electrophoretic alpha;1-Globulin Pattern of Serum in alpha;1-Antitrypsin Deficiency
###end article-title 94
###begin article-title 95
###xml 39 54 <span type="species:ncbi:10090">transgenic mice</span>
Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema
###end article-title 95
###begin article-title 96
###xml 77 81 <span type="species:ncbi:10090">mice</span>
Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice
###end article-title 96
###begin article-title 97
Upregulation of Gelatinases A and B, Collagenases 1 and 2, and Increased Parenchymal Cell Death in COPD
###end article-title 97
###begin article-title 98
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 74 82 <span type="species:ncbi:9606">patients</span>
Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema
###end article-title 98
###begin article-title 99
###xml 103 111 <span type="species:ncbi:9606">patients</span>
Increased activity of matrix metalloproteinase-8 and matrix metalloproteinase-9 in induced sputum from patients with COPD
###end article-title 99
###begin article-title 100
###xml 55 63 <span type="species:ncbi:9606">patients</span>
Increase in macrophage elastase (MMP-12) in lungs from patients with chronic obstructive pulmonary disease
###end article-title 100
###begin article-title 101
###xml 54 62 <span type="species:ncbi:9606">patients</span>
Elevated MMP-12 protein levels in induced sputum from patients with COPD
###end article-title 101
###begin article-title 102
Patterns of airway inflammation and MMP-12 expression in smokers and ex-smokers with COPD
###end article-title 102
###begin article-title 103
The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function
###end article-title 103
###begin article-title 104
Genetic Polymorphism in Matrix Metalloproteinase-9 and Pulmonary Emphysema
###end article-title 104
###begin article-title 105
The genetics of chronic obstructive pulmonary disease
###end article-title 105
###begin article-title 106
The SERPINE2 gene and chronic obstructive pulmonary disease
###end article-title 106
###begin article-title 107
Variation in the tumour necrosis factor gene is not associated with susceptibility to COPD
###end article-title 107
###begin article-title 108
Genetic variants of microsomal epoxide hydrolase and glutamate-cysteine ligase in COPD
###end article-title 108
###begin article-title 109
Cryptic haplotypes of SERPINA1 confer susceptibility to chronic obstructive pulmonary disease
###end article-title 109
###begin article-title 110
Executive Summary: Global Strategy for the Diagnosis, Management, and Prevention of COPD
###end article-title 110
###begin article-title 111
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
###end article-title 111
###begin article-title 112
FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization
###end article-title 112
###begin article-title 113
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 113
###begin article-title 114
Genotypes in matrix metalloproteinase 9 are a risk factor for COPD
###end article-title 114
###begin article-title 115
Genetic association analysis with FAMHAP: a major program update
###end article-title 115
###begin article-title 116
A powerful strategy to account for multiple testing in the context of haplotype analysis
###end article-title 116
###begin article-title 117
Posterior error probabilities and false discovery rates: two sides of the same coin
###end article-title 117
###begin article-title 118
The R Project for Statistical Computing
###end article-title 118
###begin article-title 119
Study on matrix metalloproteinase 1, 9, 12 polymorphisms and susceptibility to chronic obstructive pulmonary disease among Han nationality in northern China
###end article-title 119
###begin article-title 120
A genome-wide association study in chronic obstructive pulmonary disease (COPD): identification of two major susceptibility loci
###end article-title 120
###begin article-title 121
Matrix metalloprotease polymorphisms are associated with gas transfer in alpha 1 antitrypsin deficiency
###end article-title 121
###begin article-title 122
Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China
###end article-title 122
###begin article-title 123
Matrix metalloproteinase-9 promoter polymorphism associated with upper lung dominant emphysema
###end article-title 123
###begin article-title 124
Genetic Association Analysis of Functional Impairment in Chronic Obstructive Pulmonary Disease
###end article-title 124
###begin article-title 125
Matrix metalloproteinase gene polymorphisms: lack of association with chronic obstructive pulmonary disease in a Brazilian population
###end article-title 125

